Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Bridging the variant-to-function gap in type 2 diabetes: advances and challenges

Maynard AG., Bhardwaj R., Jones TR., Claussnitzer M.

Narrative Review on Type 2 Diabetes, published in Diabetologia (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Diabetologia (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41273414
PMCID
PMC12779665
DOI
10.1007/s00125-025-06600-6

Abstract (original English)

Type 2 diabetes is a polygenic, heterogeneous disease affecting over 530 million individuals worldwide, a number projected to rise to 1.3 billion by 2050. Genome-wide association studies have identified over 1200 loci associated with type 2 diabetes, yet only a modest proportion of disease heritability has been explained, and most risk variants lie in non-coding regions, complicating biological interpretation. This review synthesises how recent advances in variant-to-function (V2F) strategies, including fine-mapping, chromatin profiling, single-cell multi-omics, scalable CRISPR-based perturbation strategies and machine learning tools, have begun to link non-coding variants to effector genes, tissues and molecular mechanisms. We highlight examples of V2F resolution across key type 2 diabetes tissues, including the roles of TCF7L2 in pancreatic beta cell development, SLC16A11 and PNPLA3 in hepatocyte lipid metabolism, and GLUT4 trafficking pathways in adipocytes and muscle. We provide a summary table of genetically anchored, experimentally supported V2F discoveries in type 2 diabetes, and describe emerging tools and frameworks to address disease heterogeneity and context dependence. Together, these developments are on the cusp of closing the genetic association and mechanism gap while laying the foundation for future precision medicine approaches in type 2 diabetes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansDiabetes Mellitus, Type 2Genetic Predisposition to DiseaseGenome-Wide Association StudyTranscription Factor 7-Like 2 Protein

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research